GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHVF) » Definitions » Price-to-Free-Cash-Flow

Roche Holding AG (Roche Holding AG) Price-to-Free-Cash-Flow

: 15.13 (As of Today)
View and export this data going back to . Start your Free Trial

As of today (2024-04-20), Roche Holding AG's share price is $243.9799. Roche Holding AG's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $16.13. Hence, Roche Holding AG's Price-to-Free-Cash-Flow Ratio for today is 15.13.

The historical rank and industry rank for Roche Holding AG's Price-to-Free-Cash-Flow or its related term are showing as below:

RHHVF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.93   Med: 17.19   Max: 27.6
Current: 15.76

During the past 13 years, Roche Holding AG's highest Price-to-Free-Cash-Flow Ratio was 27.60. The lowest was 12.93. And the median was 17.19.

RHHVF's Price-to-Free-Cash-Flow is ranked better than
62.83% of 495 companies
in the Drug Manufacturers industry
Industry Median: 21.02 vs RHHVF: 15.76

Roche Holding AG's Free Cash Flow per Share for the six months ended in Dec. 2023 was $7.94. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $16.13.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Roche Holding AG was -13.20% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 1.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -3.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 1.80% per year.

During the past 13 years, Roche Holding AG's highest 3-Year average Free Cash Flow per Share Growth Rate was 46.20% per year. The lowest was -20.20% per year. And the median was 6.50% per year.


Roche Holding AG Price-to-Free-Cash-Flow Historical Data

The historical data trend for Roche Holding AG's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.51 22.51 19.85 17.71 17.17

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.85 - 17.71 - 17.17

Competitive Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG Price-to-Free-Cash-Flow Distribution

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Price-to-Free-Cash-Flow falls into.



Roche Holding AG Price-to-Free-Cash-Flow Calculation

Roche Holding AG's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=243.9799/16.125
=15.13

Roche Holding AG's Share Price of today is $243.9799.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $16.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Roche Holding AG  (OTCPK:RHHVF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Roche Holding AG Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (Roche Holding AG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (Roche Holding AG) Headlines

From GuruFocus